This study examined whether wearable-derived autonomic function metrics (WOMAFs) could help predict risk for Type 2 Diabetes and liver fibrosis due to MASLD. While WOMAFs alone had limited predictive value, combining them with clinical measures modestly improved risk stratification using data from the AI-READI dataset.